Clinical Edge Journal Scan

Increased prevalence of subclinical myocardial dysfunction in PsA with higher disease activity


 

Key clinical point: Patients with moderate-high psoriatic arthritis (PsA) disease activity without traditional cardiovascular risk factors had an increased prevalence of subclinical myocardial dysfunction, lower adiponectin levels, and higher serum interleukin-17A (IL-17A) levels.

Major finding: Patients with moderate and high PsA disease activity had lower global longitudinal strain (GLS), tricuspid annular plane systolic excursion, left ventricular ejection fraction, and adiponectin levels and higher IL-17A levels compared with patients with low PsA disease activity and control individuals (all P < .05). GLS was significantly associated with serum IL-17A ( P = .001) and adiponectin ( P = .032) levels.

Study details: This study included 55 patients with PsA and 25 control individuals without cardiovascular disease.

Disclosures: This study did not disclose the funding source. The authors declared no conflict of interests.

Source: Pletikosic I et al. Association of inflammatory biomarkers and disease activity with subclinical myocardial dysfunction in psoriatic arthritis. Sci Rep. 2023;13(1):10371 (Jun 26). Doi: 10.1038/s41598-023-37412-6.

Recommended Reading

Oral IL-23 receptor antagonist for psoriasis promising: Phase 2b study
MDedge Rheumatology
Keep depression, anxiety screening top of mind in patients with psoriatic disease
MDedge Rheumatology
Remote teams offer chance to improve difficult-to-treat PsA
MDedge Rheumatology
Humira biosimilars: Five things to know
MDedge Rheumatology
Beta-defensin-2 may serve as a predictive biomarker for clinical response to secukinumab in PsA
MDedge Rheumatology
Predictors of treatment response in PsA patients initiating a first TNFi
MDedge Rheumatology
Real-world study confirms clinical efficacy of ixekizumab in PsA
MDedge Rheumatology
Apremilast offers a safe long-term oral treatment option for psoriatic arthritis
MDedge Rheumatology
Improvement in patient-reported outcomes comparable with ustekinumab and TNFi in PsA
MDedge Rheumatology
Anti-TNF-α therapy reduces incidence of nailfold capillaroscopic abnormalities in PsA
MDedge Rheumatology